Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have been given a consensus recommendation of “Buy” by the ...

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) shares saw an uptick in trading volume on Tuesday . 133,137 shares traded hands during mid-day trading, an increase of 43% from the previous ...

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025On track to initiate a proof-of-concept study in ...

Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life extended ...

Oruka Therapeutics (ORKA) announced that it is expected to be added to the Nasdaq Biotechnology Index (NBI). Oruka’s addition will become effective prior to market open on Monday, December 23rd ...

MENLO PARK, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new ...

Dec. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of ...

Oruka Therapeutics, Inc. MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to ...

Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life ...

Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment ...